Roche’s ipatasertib in combination with Tecentriq and chemotherapy shows promising anti-tumour activity in triple-negative breast cancer in early phase trial

Matthew Durham
Omnidynamic Marketing

Joey Cohen
Medication Adherence

Brenda Snow
Authentic Patient Voice

Frank Burrell
Scientific Storytelling

Amy Giles
Increasing Engagement

Suma Ramadas, PhD
Medical Affairs

Daniel Sontupe
Market Access

Paul Theisen
Patient Acquisition

Pat Purcell
Meeting Engagement

Liz Kane
Impactful Strategy

Stacey Gandler
Brand Nourishment

David Linetsky
Point-of-Care Marketing

Bud Bilanich
Success Coach

Matt Turner
Patient Affordability